1Postgraduate Student, Department of Biochemistry and Microbiology, Faculty of Pharmacy, Tishreen University, Lattakia, Syria
2Assistant Professor, Department of Internal Medicine and Hematology, Faculty of Medicine, Tishreen University, Lattakia, Syria
3Assistant Professor, Department of Biochemistry and Microbiology, Faculty of Pharmacy, Tishreen University, Lattakia, Syria
*Corresponding Author E-mail: asala.raya93@gmail.com
Online published on 27 February, 2023.
Breast cancer is the most common tumor among women worldwide, and elevated pretreatment serum ferritin levels are a poor prognostic factor in patients with many malignancies, but the relationship between serum ferritin levels and disease prognosis in breast cancer patients remains unclear.
To estimate the relationship between pretreatment serum ferritin, overall survival (OS) and progression-free survival (PFS) in breast cancer patients.
We evaluated pretreatment serum ferritin in 96 newly diagnosed breast cancer patients who have been followed up for 27months. Statistical analysis was performed using MedCalc (version 19.1.6). A p value <0.05 was considered statistically significant.
Among patients with serum ferritin levels less than 146ng/ml, the estimated mean PFS survival was 26.561±0.328 months compared to 15.212±1.396 months for those with serum ferritin levels 146ng/ml or higher (p=0.001). The estimated mean OS survival for patients with serum ferritin levels < 146ng/ml was 27 months, compared to 23.533±1.224 months for patients with serum ferritin levels > 146ng/ml (P=0.002), their 27 months OS survival rates were 68.75% and 27.08%, respectively (p=0.008).
Serum ferritin can be useful prognostic factor for PFS and OS in breast cancer patients, and elevated levels of it at 146ng/ml or more are a poor prognostic factor for 27month survival rates.
Breast cancer, Serum ferritin, Prognosis, Progression-free survival, Overall survival
